Skip to main content

and
  1. Article

    Open Access

    Anti-tumor effects of tirbanibulin in squamous cell carcinoma cells are mediated via disruption of tubulin-polymerization

    Topical tirbanibulin is a highly effective and well tolerated novel treatment option for actinic keratoses (AKs). This study aimed to characterize the mode of action of tirbanibulin in keratinocytes (NHEK) and...

    Viola K. DeTemple, Antje Walter, Sabine Bredemeier in Archives of Dermatological Research (2024)

  2. No Access

    Article

    Fokale dermale Hypoplasie durch pathogene Variante im PORCN-Gen in postzygotischer, unilateraler Mosaik-Konstellation

    Wir berichten über eine 29-jährige Patientin mit ab dem Grundschulalter bemerkbaren diskreten zum Teil erythematösen, zum Teil hyperpigmentierten Streifen entlang der Blaschko-Linien an der rechten Körperhälft...

    Eleni Koutra, Elke Lusmöller, Judith Fischer, Katalin Komlosi in Die Dermatologie (2024)

  3. No Access

    Article

    Kutane Nebenwirkungen onkologischer Systemtherapien

    Bestimmte medikamentöse Tumortherapien verursachen kutane Toxizität an Händen, Füßen und Nägeln.

    Selma Ugurel, Prof. Dr. Claudia Pföhler, Ralf Gutzmer in Die Dermatologie (2024)

  4. Article

    Open Access

    Health-Related Quality of Life with Pembrolizumab in Patients with Locally Advanced or Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: KEYNOTE-629

    At first interim analysis of KEYNOTE-629, health-related quality of life (HRQoL) with pembrolizumab was stable or improved over 48 weeks in recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC...

    Åse Bratland, Eva Munoz-Couselo, Laurent Mortier, Osama Roshdy in Dermatology and Therapy (2023)

  5. Article

    Open Access

    Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis

    Sonidegib is approved to treat locally advanced basal cell carcinoma (laBCC) in the USA, EU, Switzerland, and Australia and metastatic basal cell carcinoma (mBCC) in Switzerland and Australia in patients not a...

    Ralf Gutzmer, Carmen Loquai, Caroline Robert, Brigitte Dréno in Dermatology and Therapy (2021)

  6. No Access

    Article

    Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe

    Talimogene laherparepvec, a herpes simplex virus type 1-based intrale-sional oncolytic immunotherapy, is approved in Europe for the treatment of adults with unresectable stage IIIB-IVM1a melanoma, with no bone...

    Ralf Gutzmer, Kevin J. Harrington, Christoph Hoeller in European Journal of Dermatology (2018)

  7. No Access

    Article

    The histamine H4 receptor modulates the differentiation process of human monocyte-derived M1 macrophages and the release of CCL4/MIP-1β from fully differentiated M1 macrophages

    Histamine is an important mediator of biological functions and present in high amounts in inflammatory skin lesions which are characterised by a marked infiltration of myeloid derived cell populations. The aim...

    Susanne Mommert, Lisanne Ratz, Holger Stark, Ralf Gutzmer in Inflammation Research (2018)

  8. No Access

    Article

    15. Mainzer Allergie-Workshop 2003

    Prof. Dr. J. Saloga, Prof. Dr. J. Knop, H. P. Rihs, B. Dumont in Allergo Journal (2003)

  9. No Access

    Article

    Amikrobielle intertriginöse Pustulose bei Autoimmunerkrankungen – Eine neue Entität?

    Olliver Hoch, Rudolf A. Herbst, Ralf Gutzmer, Peter Kiehl, Alexander Kapp in Der Hautarzt (1998)

  10. No Access

    Article

    Das Bart-Syndrom – Eigene Entität oder Variante einer Epidermolysis bullosa?

    Ralf Gutzmer, Rudolf A. Herbst, Jost Becker, Peter Kiehl in Der Hautarzt (1997)

  11. No Access

    Article

    Das SAPHO-Syndrom Fallbeschreibung von drei Patienten mit Akne conglobata und osteoartikulären Symptomen

    Ralf Gutzmer, Rudolf A. Herbst, Alexander Kapp, Jürgen Weiß in Der Hautarzt (1997)